Cyclacel Pharmaceuticals Inc Share Price Nasdaq
Equities
US23254L3069
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
14/05 | Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
14/05 | Transcript : Cyclacel Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024 |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 3.19M 266M |
---|---|---|---|---|---|
Net income 2024 * | -11M -916M | Net income 2025 * | -19M -1.58B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.3
x | P/E ratio 2025 * |
-0.39
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.14% |
Latest transcript on Cyclacel Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 01/97/01 |
Paul McBarron
DFI | Director of Finance/CFO | 63 | 01/02/01 |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 17/20/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 83 | 01/06/01 | |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 17/20/17 |
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 01/97/01 |
1st Jan change | Capi. | |
---|---|---|
+9.63% | 115B | |
+13.16% | 107B | |
-13.40% | 22.31B | |
-3.46% | 21.6B | |
-5.29% | 18.23B | |
-38.57% | 17.62B | |
+8.18% | 14.26B | |
+34.60% | 12.37B | |
-26.51% | 8.28B |